Twin-Reversed Arterial Perfusion Sequence disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

TRAP MCID: TWN015 MIFTS: 31	Twin-Reversed Arterial Perfusion Sequence (TRAP) Categories: Rare diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Twin-Reversed Arterial Perfusion Sequence

MalaCards integrated aliases for Twin-Reversed Arterial Perfusion Sequence:

Name: Twin-Reversed Arterial Perfusion Sequence ⁵⁸

Trap ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁸

Rare gynaecological and obstetric diseases

External Ids:

Orphanet ⁵⁸ ORPHA617297

Sources

Summaries for Twin-Reversed Arterial Perfusion Sequence

MalaCards based summary: Twin-Reversed Arterial Perfusion Sequence, also known as trap, is related to endocarditis and neural tube defects. The drugs Certoparin and Heparin, bovine have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, eye and bone marrow.

Sources

Related Diseases for Twin-Reversed Arterial Perfusion Sequence

Diseases related to Twin-Reversed Arterial Perfusion Sequence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1057)

#	Related Disease	Score
1	endocarditis	11.0
2	neural tube defects	11.0
3	myeloperoxidase deficiency	11.0
4	hidradenitis suppurativa	10.9
5	immune system disease	10.9
6	polyhydramnios	10.7
7	preterm premature rupture of the membranes	10.6
8	twin-to-twin transfusion syndrome	10.5
9	acardia	10.5
10	malaria	10.5
11	dengue disease	10.4
12	common cold	10.4
13	selective intrauterine growth restriction	10.4
14	charge syndrome	10.4
15	hair whorl	10.3
16	hydrops fetalis, nonimmune	10.3
17	disseminated intravascular coagulation	10.3
18	congestive heart failure	10.3
19	autoimmune disease	10.3
20	global developmental delay, lung cysts, overgrowth, and wilms tumor	10.3
21	vasculitis	10.3
22	macular degeneration, age-related, 1	10.3
23	adult respiratory distress syndrome	10.3
24	vaccinia	10.2
25	parkinson disease, late-onset	10.2
26	lung cancer	10.2
27	microvascular complications of diabetes 5	10.2
28	chikungunya	10.2
29	chronic bilirubin encephalopathy	10.2
30	systemic lupus erythematosus	10.2
31	west nile virus	10.2
32	rapidly involuting congenital hemangioma	10.2
33	hydrocephalus, congenital, 1	10.2
34	spastic ataxia, charlevoix-saguenay type	10.2
35	patent ductus arteriosus 1	10.2
36	leukemia, acute lymphoblastic 3	10.2
37	deficiency anemia	10.2
38	b-lymphoblastic leukemia/lymphoma	10.2
39	microcephaly	10.2
40	pericardial effusion	10.2
41	heart septal defect	10.2
42	atrial heart septal defect	10.2
43	teratoma	10.2
44	holoprosencephaly	10.2
45	hydranencephaly	10.2
46	polycythemia	10.2
47	phocomelia	10.2
48	interatrial communication	10.2
49	twin anemia-polycythemia sequence	10.2
50	gastric antral vascular ectasia	10.2

Graphical network of the top 20 diseases related to Twin-Reversed Arterial Perfusion Sequence:

Sources

Symptoms & Phenotypes for Twin-Reversed Arterial Perfusion Sequence

Sources

Drugs & Therapeutics for Twin-Reversed Arterial Perfusion Sequence

Drugs for Twin-Reversed Arterial Perfusion Sequence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Certoparin

Approved, Investigational

Phase 4

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 4

9005-49-6

22833565 9812414 772

Reviparin

Approved, Investigational

Phase 4

9041-08-1

Aflibercept

Approved

Phase 4

862111-32-8

124490314

Verteporfin

Approved, Investigational

Phase 4

129497-78-5

5362420

Ranibizumab

Approved

Phase 4

347396-82-1

Rilonacept

Approved, Investigational

Phase 4

501081-76-1

Fibrinolytic Agents

Phase 4

Anticoagulants

Phase 4

Calcium heparin

Phase 4

Heparin, Low-Molecular-Weight

Phase 4

Angiogenesis Inhibitors

Phase 4

Anti-Inflammatory Agents

Phase 4

Vaccines

Phase 4

Pharmaceutical Solutions

Phase 4

Immunologic Factors

Phase 4

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Pertuzumab

Approved

Phase 3

380610-27-5

Trastuzumab

Approved, Investigational

Phase 3

180288-69-1

Endothelial Growth Factors

Phase 3

Mitogens

Phase 3

Dermatologic Agents

Phase 3

Photosensitizing Agents

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Temozolomide

Approved, Investigational

Phase 2

85622-93-1

5394

Docetaxel

Approved, Investigational

Phase 1, Phase 2

114977-28-5

148124

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Colchicine

Approved

Phase 2

64-86-8

2833 6167

Capecitabine

Approved, Investigational

Phase 1, Phase 2

154361-50-9

60953

Topotecan

Approved, Investigational

Phase 2

123948-87-8, 119413-54-6

60699 60700

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Dantrolene

Approved, Investigational

Phase 1, Phase 2

7261-97-4

6914273

Histamine

Approved, Investigational

Phase 1, Phase 2

51-45-6

774

Pirfenidone

Approved, Investigational

Phase 1, Phase 2

53179-13-8

40632

Clemastine

Approved, Investigational

Phase 1, Phase 2

15686-51-8

26987

Pioglitazone

Approved, Investigational

Phase 1, Phase 2

111025-46-8

4829

Metronidazole

Approved

Phase 1, Phase 2

443-48-1, 69198-10-3

4173

Artesunate

Approved, Investigational

Phase 1, Phase 2

88495-63-0

6917864 5464098

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Zoledronic acid

Approved

Phase 2

118072-93-8

68740

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Cadexomer iodine

Experimental

Phase 2

94820-09-4

Ifetroban

Investigational

Phase 2

143443-90-7

3037233

Pyronaridine

Investigational

Phase 1, Phase 2

74847-35-1

5485198

Vitamins

Phase 2

Interventional clinical trials:

(show top 50) (show all 114)

#	Name	Status	NCT ID	Phase	Drugs
1	Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy	Unknown status	NCT02621645	Phase 4
2	Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial	Unknown status	NCT00196417	Phase 4	Standard heparin (UFH) versus certoparin (LMWH)
3	Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy	Completed	NCT02072408	Phase 4	aflibercept
4	Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab	Completed	NCT02309281	Phase 4	aflibercept 2mg
5	An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy	Completed	NCT01950741	Phase 4	aflibercept
6	Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)	Completed	NCT01663103	Phase 4	Rilonacept;Placebo
7	An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration	Completed	NCT01722045	Phase 4	Intravitreal Aflibercept Injection (IAI)
8	Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples	Active, not recruiting	NCT01824537	Phase 4
9	A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD)	Completed	NCT00637377	Phase 3	Ranibizumab
10	A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration	Completed	NCT00509795	Phase 3
11	A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion	Completed	NCT00943072	Phase 3	Sham
12	Trial to Reduce Alloimmunization to Platelets (TRAP)	Completed	NCT00000589	Phase 3
13	A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)	Completed	NCT01012973	Phase 3
14	An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration	Completed	NCT00964795	Phase 3	Intravitreal Aflibercept Injection 2mg
15	A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia	Completed	NCT01249664	Phase 3
16	An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema	Completed	NCT01512966	Phase 3
17	A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema	Completed	NCT01363440	Phase 3	Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
18	A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema	Completed	NCT01783886	Phase 3
19	A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion	Completed	NCT01521559	Phase 3	Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
20	A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration	Completed	NCT01482910	Phase 3	Visudyne
21	A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema	Completed	NCT01331681	Phase 3
22	The Efficacy of the Addition of TRAstuzumab and Pertuzumab to Neoadjuvant Chemoradiation: a Randomized Multi-center Study in Resectable HER2 Overexpressing Adenocarcinoma of the Esophagus or Gastroesophageal Junction. The TRAP-2 Study	Recruiting	NCT05188313	Phase 3	Trastuzumab;Pertuzumab;Paclitaxel;Carboplatin
23	A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer	Unknown status	NCT01652196	Phase 2	oxaliplatin;leucovorin;fluorouracil
24	Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With AdCh63 ME-TRAP and MVA ME-TRAP	Completed	NCT00890760	Phase 1, Phase 2
25	A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP	Completed	NCT01142765	Phase 1, Phase 2
26	A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children	Completed	NCT01635647	Phase 1, Phase 2
27	A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy	Completed	NCT00729157	Phase 2
28	A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00462826	Phase 2
29	A Phase I/IIa Sporozoite Challenge Study to Assess the Safety, Immunogenicity and Protective Efficacy of Intravenous Boosting With Malaria Vaccine Candidates ChAd63 and MVA Encoding ME-TRAP	Completed	NCT03707353	Phase 1, Phase 2
30	A Randomized, Single-Masked , Long-Term, Safety and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects With Neovascular Age-related Macular Degeneration	Completed	NCT00527423	Phase 2	VEGF Trap Eye
31	A Nonrandomized, Open-label Study to Evaluate the Safety and Pharmacokinetics of Multiple Administration of RC28-E Injection (a Chimeric Decoy Receptor Trap Fusion Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Wet Age-Related Macular Degeneration	Completed	NCT04270669	Phase 1, Phase 2
32	Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	Completed	NCT00436501	Phase 1, Phase 2	docetaxel
33	Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline and/or Taxane	Completed	NCT00369655	Phase 2
34	A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA Encoding ME-TRAP and Also RTS,S/AS01B Alone.	Completed	NCT01883609	Phase 1, Phase 2
35	A Multicenter, Open-label, Single-arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites	Completed	NCT00396591	Phase 2	Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
36	A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Concomitant Administration of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01¬B + ChAd63 and MVA Encoding ME-TRAP and Also RTS,S/AS01B Alone	Completed	NCT02252640	Phase 1, Phase 2
37	A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema (DME)	Completed	NCT00789477	Phase 2	Intravitreal Aflibercept Injection
38	Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+Esophageal Carcinoma: the TRAP Study	Completed	NCT02120911	Phase 1, Phase 2	Pertuzumab, trastuzumab
39	A Phase 2 Study Evaluating the Efficacy of VEGF Trap in Patients With Recurrent Inoperable Stage III or Stage IV Melanoma	Completed	NCT00450255	Phase 2
40	Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer	Completed	NCT00407654	Phase 2	aflibercept
41	A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium	Completed	NCT00407485	Phase 2
42	Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With the Virosomal Vaccine PEV3A and FP9-MVA ME-TRAP. A Phase I / IIa Controlled Challenge Trial	Completed	NCT00408668	Phase 1, Phase 2
43	A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas	Completed	NCT00390234	Phase 2	ziv-aflibercept
44	Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas	Completed	NCT00369590	Phase 2
45	A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS	Completed	NCT01623557	Phase 1, Phase 2
46	Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF)	Completed	NCT00582907	Phase 2	Rilonacept;Placebo
47	Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects With Autoinflammatory Diseases: A Therapeutic Approach to Study Pathogenesis	Completed	NCT00094900	Phase 2	IL-1 Trap
48	Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection.	Completed	NCT01666925	Phase 2
49	X-TRAP: Phase I/II Study of Capecitabine Plus Aflibercept in Metastatic Colorectal Cancer	Completed	NCT01661972	Phase 1, Phase 2	Capecitabine and aflibercept
50	Efficacy Study of ChAd63-MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection	Completed	NCT01658696	Phase 2

Search NIH Clinical Center for Twin-Reversed Arterial Perfusion Sequence

Sources

Genetic Tests for Twin-Reversed Arterial Perfusion Sequence

Sources

Anatomical Context for Twin-Reversed Arterial Perfusion Sequence

Organs/tissues related to Twin-Reversed Arterial Perfusion Sequence:

MalaCards : Neutrophil, Eye, Bone Marrow, Bone, Endothelial, Liver, Lung

Sources

Publications for Twin-Reversed Arterial Perfusion Sequence

Articles related to Twin-Reversed Arterial Perfusion Sequence:

(show top 50) (show all 30116)

#	Title	Authors	PMID	Year
1	Effects of platelets activated by different agonists on fibrin formation and thrombin generation. ⁶²	Muravlev IA...Mazurov AV	36325627	2023
2	Unravelling mechanisms of protein and lipid oxidation in mayonnaise at multiple length scales. ⁶²	Yang S...Hohlbein J	36303379	2023
3	Determination and speciation of methyl mercury and total mercury in fish tissue samples by gold-coated W-coil atom trap cold vapor atomic absorption spectrometry. ⁶²	Atasoy M...Vaizogullar AI	36099824	2023
4	Do neighbourhood traffic-related air pollution and socio-economic status moderate the associations of the neighbourhood physical environment with cognitive function? Findings from the AusDiab study. ⁶²	Cerin E...Anstey KJ	36368384	2023
5	Long-term exposure to traffic-related air pollution and stroke: A systematic review and meta-analysis. ⁶²	Haddad P...Hoffmann B	36446272	2023
6	Vanadium dioxide plates reduced graphene oxide as sulfur cathodes for efficient polysulfides trap in long-life lithium-sulfur batteries. ⁶²	Chen B...Chen T	36152613	2023
7	Determining Protein-Protein Interaction with GFP-Trap Beads. ⁶²	Yilmazer I...Sharma M	36107351	2023
8	Sensor-based evaluation of a Urine Trap toilet in a shared bathroom. ⁶²	Kachoria P...Grego S	36202366	2023
9	Modulations in human neutrophil metabolome and S-glutathionylation of glycolytic pathway enzymes during the course of extracellular trap formation. ⁶²	Awasthi D...Dikshit M	36265832	2023
10	Effects of long term diabetogenic high fat diet on bone in ovariectomized female rats. ⁶²	Dai F...Zhang Q	35762155	2023
11	A rescue diet raises the plasma calcium concentration and ameliorates rheumatoid arthritis in mice: Role of CaSR-mediated inhibition of osteoclastogenesis. ⁶²	Yang Q...Sun W	36468692	2023
12	Parallel Pseudo-MRM on the "brick" miniature mass spectrometer for high throughput multi-target screening. ⁶²	Zhang H...Xu W	36041316	2023
13	Degradation of 3D-printed magnesium phosphate ceramics in vitro and a prognosis on their bone regeneration potential. ⁶²	Eugen G...Elke V	35574054	2023
14	Neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases. ⁶²	Herre M...Olsson AK	35951483	2023
15	Comparison of destructive and nondestructive DNA extraction methods for the metabarcoding of arthropod bulk samples. ⁶²	Kirse A...Zizka VMA	35932285	2023
16	Exposure to a real traffic environment impairs brain cognition in aged mice. ⁶²	Xu C...Jin Y	36113572	2022
17	PKC-SWI6 signaling regulates asexual development, cell wall integrity, stress response, and lifestyle transition in the nematode-trapping fungus Arthrobotrys oligospora. ⁶²	Xie M...Yang J	35829807	2022
18	Histochemical assessment on osteocytic osteolysis in lactating mice fed with a calcium-insufficient diet. ⁶²	Hongo H...Li M	36152933	2022
19	Simultaneous detection of sibutramine and phenolphthalein in a diet jelly health food product that caused health problems. ⁶²	Fukiwake T...Akiyama H	36472786	2022
20	Association Between Physical Performance Tests and External Load During Scrimmages in Highly Trained Youth Ice Hockey Players. ⁶²	Byrkjedal PT...Spencer M	36470253	2022
21	Eosinophils: Focus on DNA extracellular traps. ⁶²	Thompson-Souza GA...Neves JS	36379309	2022
22	Cell pairing for biological analysis in microfluidic devices. ⁶²	Tang X...Liu X	36389274	2022
23	Characterization of radicals in polysorbate 80 using electron paramagnetic resonance (EPR) spectroscopy and spin trapping. ⁶²	Mittag JJ...Garidel P	35795322	2022
24	Perspective of 2D Integrated Electronic Circuits: Scientific Pipe Dream or Disruptive Technology? ⁶²	Waltl M...Grasser T	35318749	2022
25	Impact of melatonin on periodontal ligament fibroblasts during mechanical strain. ⁶²	Schroder A...Kirschneck C	35396993	2022
26	Neutrophils Protect Against Staphylococcus aureus Endocarditis Progression Independent of Extracellular Trap Release. ⁶²	Meyers S...Martinod K	36453281	2022
27	Performance of the cervical shortening for prediction of spontaneous preterm birth in uncomplicated twins. ⁶²	Meller C...Otano L	34570673	2022
28	Placenta-specific protein 1 (PLAC1) expression is significantly down-regulated in preeclampsia via a hypoxia-mediated mechanism. ⁶²	Devor EJ...Santillan MK	34565269	2022
29	FAEE exerts a protective effect against osteoporosis by regulating the MAPK signalling pathway. ⁶²	Wang MY...Sheng J	35180021	2022
30	TET2 regulates osteoclastogenesis by modulating autophagy in OVX-induced bone loss. ⁶²	Yang C...Geng D	35255774	2022
31	Traffic-related air pollution and genome-wide DNA methylation: A randomized, crossover trial. ⁶²	Du X...Kan H	35963411	2022
32	Na+ Selective Binding by Beauvericin and Its Mechanism Studied by Mass-Coupled Cold Ion Trap Infrared Spectroscopy. ⁶²	Vo KX...Fujii M	36454047	2022
33	The Role of Bone Grafts in Preventing Medication-Related Osteonecrosis of the Jaw: Histomorphometric, Immunohistochemical, and Clinical Evaluation in Animal Model. ⁶²	da Silva JR...Hochuli-Vieira E	36387320	2022
34	An anticomplement homogeneous polysaccharide from Hedyotis diffusa attenuates lipopolysaccharide-induced acute lung injury and inhibits neutrophil extracellular trap formation. ⁶²	Zhang J...Chen D	36116199	2022
35	25-Hydroxycholesterol induces odontoclastic differentiation through RANK-RANKL upregulation and NF-κB activation in odontoblast-like MDPC-23 cells: An in vitro study. ⁶²	Lim HI...Kim JS	36462163	2022
36	The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. ⁶²	Bu MT...Hugo W	35577211	2022
37	Epigallocatechin-3-gallate reduces neutrophil extracellular trap formation and tissue injury in severe acute pancreatitis. ⁶²	Li H...Zhang Y	35983712	2022
38	Microplastics: Is There Any Environmental Information about Insect Glue Trap Plastic (IGTP)? ⁶²	Tziourrou P...Papatheodorou E	36459460	2022
39	Citrinin stimulated heterophil extracellular trap formation in chickens. ⁶²	Chen Y...Zhou E	36244215	2022
40	Timing of intra-fetal laser therapy for twin reversed arterial perfusion (TRAP) sequence: Retrospective series and systematic review and meta-analysis. ⁶²	Vitucci A...Prefumo F	35435256	2022
41	Post-traumatic hamatolunate impingement: A diagnostic trap. Comment to: Hamatolunate impingement syndrome in golfers: Results of arthroscopic burring of the apex of the hamate (April 2022). ⁶²	de Villeneuve Bargemon JB...Levadoux M	36113761	2022
42	Over 31% efficient indoor organic photovoltaics enabled by simultaneously reduced trap-assisted recombination and non-radiative recombination voltage loss. ⁶²	Zhou X...Ma W	36458496	2022
43	Genetic algorithm parallel optimization of a new high mass resolution planar electrostatic ion trap mass analyzer. ⁶²	Wang W...Ding L	36413223	2022
44	Impurity profile and spectrum characteristics of the isomers in cefamandole nafate using high- performance liquid chromatography/high-performance size exclusion chromatography tandem ion trap/time-of-flight mass spectrometry. ⁶²	Wang F...Hong L	36114650	2022
45	Differential metabolic profiles of ginsenosides in artificial gastric juice using ultra-high-pressure liquid chromatography coupled with linear ion trap-Orbitrap mass spectrometry. ⁶²	Huang J...Zhang J	36044184	2022
46	Probing Intrinsic Defect-Induced Trap States and Hopping Transport in Two-Dimensional PdSe2 Semiconductor Devices. ⁶²	Wang Z...Yoo WJ	36474350	2022
47	Crystalline Phases Regulate Electronic Trap States at Defective Surfaces of Lead Halide Perovskites. ⁶²	Feng Q...Nan G	36469403	2022
48	Verifying the efficiency of the Biogents Sentinel trap in the field and investigating microclimatic influences on responding Aedes aegypti behavior. ⁶²	Amos BA...Carde RT	36314670	2022
49	[Remaining a physician-how to escape the commercialization trap]. ⁶²	Gerheuser F	36471173	2022
50	Major anthocyanins in elderberry effectively trap methylglyoxal and reduce cytotoxicity of methylglyoxal in HepG2 cell line. ⁶²	Ferreira SS...Nunes FM	36281231	2022